Avalo Therapeutics, Inc. · NASDAQ:AVTX
BVF PARTNERS L P/IL reported a 9.99% stake in Avalo Therapeutics, Inc. (Schedule 13G/A)
Event Sep 30, 2025 · Filed Nov 14, 2025
BVF PARTNERS L P/IL reported a 9.99% stake in Avalo Therapeutics, Inc., 1,458,151 shares, as a passive investor on Sep 30, 2025. Filed Nov 14, 2025 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 1,458,151
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 5.50% | 806,414 |
| BVF I GP LLC | 5.50% | 806,414 |
| BIOTECHNOLOGY VALUE FUND II LP | 4.00% | 580,975 |
| BVF II GP LLC | 4.00% | 580,975 |
| Biotechnology Value Trading Fund OS LP | 0.30% | 40,633 |
| BVF Partners OS Ltd. | 0.30% | 40,633 |
| BVF GP HOLDINGS LLC | 9.50% | 1,387,389 |
| BVF PARTNERS L P/IL | 9.99% | 1,458,151 |
| BVF INC/IL | 9.99% | 1,458,151 |
| LAMPERT MARK N | 9.99% | 1,458,151 |
Source
Related
- Avalo Therapeutics, Inc.
- Bvf Partners L P
- Avalo Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · Aug 14, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2026
- Schedule 13G/A · Bvf Partners L P · Feb 17, 2026
- Schedule 13G/A · Bvf Partners L P · Feb 14, 2025
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Doyle Mittie · Sep 1, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 19, 2026